ALPH — AlphaHelix Molecular Diagnostics AB (publ) Balance Sheet
0.000.00%
Last trade - 00:00- SEK21.56m
- SEK19.03m
- SEK26.67m
Annual balance sheet for AlphaHelix Molecular Diagnostics AB (publ), fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
R2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Interim Report | ARS | ARS | PRESS | ARS |
| Standards: | — | SAS | SAS | — | SAS |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 0.412 | 1.42 | 5.86 | 7.84 | 3.63 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | 3.26 | 3.2 | 8.8 | 5.73 | 4.66 |
| Total Inventory | |||||
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 8.29 | 9.81 | 21.7 | 20.1 | 13.3 |
| Net Property, Plant And Equipment | 0.504 | 0.093 | 0.075 | 0.118 | 0.123 |
| Net Goodwill | |||||
| Net Intangible Assets | |||||
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 8.79 | 9.9 | 32.1 | 28.8 | 19.1 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 7.31 | 6 | 8.15 | 7.69 | 8.03 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Deferred Income Tax | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 7.31 | 6.9 | 9.95 | 8.91 | 8.68 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 1.49 | 3 | 22.1 | 19.9 | 10.4 |
| Total Liabilities & Shareholders' Equity | 8.79 | 9.9 | 32.1 | 28.8 | 19.1 |
| Total Common Shares Outstanding |